Latest / Psychopharmacology Today / Ep. 11: The Science Behind Psychedelics
Transcript
- 0:05Dr. Judi Steinman is an adjunct professor in Alliant University's Master
- 0:09of Science in Clinical Psychopharmacology and was program director from 2017
- 0:15to 2022. She served as the president of APA's Society of Prescribing Psychology,
- 0:21Division 55, in 2019, and as past president from 2020 to 2022.
- 0:27She co-chairs the Division 55 Training Program Director Council and is
- 0:32Founding Chair of the Division 55 Legislative and Social Action Committee.
- 0:36She coauthored the Division's specialty petition to APA's CRSPPP,
- 0:42allowing clinical psychopharmacology to be recognized as a specialty.
- 0:46Dr. Steinman serves as a chair of the Hawaii and Florida Psychological Associations'
- 0:52RxP committees. She is actively engaged in efforts to bring prescriptive authority
- 0:57for qualified psychologists in Hawaii,
- 1:00Florida, and
- 1:01and across the globe. She trains graduates from all of the MSCP programs
- 1:06for the National PEP exam. So welcome,
- 1:10Dr. Steinman, and you have the floor.
- 1:12It's so wonderful to see so many friends who are here today and hopefully some
- 1:17new friends. I actually am in Florida now.
- 1:21I've been here for six years, but ~ spent quite a few years in Hawaii.
- 1:28I ran ~ the MSCP program that was in Hawaii.
- 1:33And as some of you may be familiar,
- 1:36~ we've been trying to get prescriptive authority in Hawaii
- 1:41for 40-plus years. And ~ we did it.
- 1:46We did it like two weeks ago, it's done.
- 1:50So ~ Hawaii is officially the ninth state.
- 1:54And in my mind, it's really the tenth state,
- 1:57but that would be a whole other lecture in and of itself.
- 2:00Because we all forget that in Indiana,
- 2:04there was a rule that would allow a prescribing psychologist who's allowed
- 2:10to prescribe in the military to practice there in Indiana.
- 2:15But that's a that's a long story.
- 2:17That's another talk. I'm gonna ~ tell you a little story.
- 2:21Unlike just about everybody else that you might meet in this field
- 2:26of ~ psychopharmacology, I'm a bench scientist.
- 2:30I grew up doing biochemical analysis of monoamines
- 2:35in the spinal cord and peptides and monoamines in the brain.
- 2:40And ~ I was ~ a pharmacologist.
- 2:44I mean, my degree was in psychology,
- 2:48but I was doing something that is called or used to
- 2:51be called physiological psychology.
- 2:54So I was always focused in on the science of psychology.
- 2:59And one of the things that was really interesting to me back in the day
- 3:04was this whole idea about what is it that hallucinogenic drugs do to the brain?
- 3:11And this is long before there was really a thought about having therapy-based
- 3:17administration of psychedelics.
- 3:20Over the last 10 years or so,
- 3:23there's been an enormous change in the field.
- 3:27And so I thought I'd bring some of this to you today.
- 3:30So I've been doing talks for about two years now on native ritual practices
- 3:38and the use of different drugs and especially in terms of how those substances,
- 3:44even though they're coming from plants,
- 3:46~ have psychogenic effects and that they potentially have interactions
- 3:52with medication that a person might be taking.
- 3:55And, you know, with a special concern about ~ folks in the Native American,
- 4:01Native Indian ~ populations,
- 4:04where they may not always be forthright in talking to you about their ritual uses.
- 4:10So I got very interested in this field and ~ have been talking about it
- 4:15for a couple of years.
- 4:16Somebody told me once... he's a professor at an undergraduate and graduate school
- 4:23~ in psychology. And he told me that his upcoming students really
- 4:29are not interested in psychopharmacology.
- 4:33They're really interested in psychedelics.
- 4:36The thought in my mind as a traditional bench scientist that people make that
- 4:42distinction and don't understand how psychedelics really are part
- 4:46of clinical psychopharmacology.
- 4:48And that, ~ you know, the training,
- 4:51for example, the MSCP that we offer at Alliant or the other schools around
- 4:56the country now, that there really should not be a distinction.
- 5:00But
- 5:01there's a younger generation that thinks of prescribed medications
- 5:07as somehow being disconnected from hallucinogens or psychedelics,
- 5:13if you will. And I will use those terms interchangeably.
- 5:16So I just found that kind of fascinating,
- 5:18you know, the fact that they're really interested in psychopharmacology,
- 5:23but they don't understand that connection between the two.
- 5:27I feel it's our mandate as educators to bring the story
- 5:33to the people who are going to potentially be prescribing psychologists
- 5:37in the future or therapists that are utilizing psychogenic drugs.
- 5:42So that's sort of my orientation in talking on this tonight.
- 5:47Whether you've read it in a book or seen it in a movie or had a personal experience,
- 5:52there are common
- 5:54hallucinogenic effects of many different substances,
- 5:59whether they come directly from ~ plants or fungi,
- 6:05right? You know, I'm a "fun-gal," right?
- 6:08~ You know, from a fungus, or ~ whether they're synthesized
- 6:14and created into a ~ controlled substance.
- 6:19And I'm using controlled substance a little differently than the way
- 6:22the DEA uses it. But for right now,
- 6:25you know, when you take a chemical and synthesize
- 6:30it and resynthesize it, and you can measure the amount of that substance,
- 6:36and then we can come up with prescribing ~ suggestions and things like that.
- 6:42But the things that people, whether they're taking these substances
- 6:47recreationally or as self-medication or in a therapeutic setting
- 6:54of some kind, the idea that there are certain things that are common with many
- 6:59of our hallucinogens, okay? So really to be a hallucinogen,
- 7:04the person who's taking the substance is going to experience changes
- 7:09in their perception of time
- 7:12and space. So their awareness of themselves will change.
- 7:18~ They have not just an increased sensitivity to ~ the sensory world,
- 7:25but they'll have something called synesthesia,
- 7:28which blends our different senses.
- 7:31And I will talk about that a little bit ~ in terms of LSD as a superagonist,
- 7:38which is not a term that everybody uses,
- 7:40but
- 7:41I'm pretty convinced that of all of our substances that we'll talk about today,
- 7:48that there is a very unique property about LSD that,
- 7:53and I'll give you the punchline now,
- 7:55that it is not only affecting 5-HT 2 receptors,
- 8:01Serotonin 2 receptors, but it's also modifying glutaminergic
- 8:08receptors.
- 8:09And so glutamine, of course, is an amino acid that,
- 8:13or it's amino acid-derived, I should say,
- 8:16~ neurotransmitter. It's just a simple amino acid
- 8:22and it has its own neurons that it gets released from.
- 8:26It has its own receptors, and there's a number of different kinds
- 8:31of receptors that glutamate binds to.
- 8:33But it's something unique that
- 8:35really all of our hallucinogens,
- 8:37especially the ones that have indolamines,
- 8:39I'll talk to you about what that means in a minute,
- 8:42that they have this additional ability to ~ form a complex with
- 8:48the serotonin receptor and the glutaminergic receptor.
- 8:53And that is what is most likely responsible for
- 8:58~ at least synesthesia and paresthesia,
- 9:01where, you know, you
- 9:02feel what you see, you hear what you are tasting,
- 9:06you know, things like that, that really bend ~ our understanding
- 9:12of what sensations are to the body and to the mind.
- 9:15But these are the general ~ things that ~ people will report experiencing
- 9:22~ with hallucinogens. And this is a list.
- 9:25I just like the colors in it.
- 9:27But it does have a pretty thorough list here.
- 9:31I am not going to talk about all of these substances tonight.
- 9:35But we have certain ones that bind very specifically
- 9:39to serotonergic ~ receptors. That's going to be LSD.
- 9:44We have ~ psilocybin. Psilocybin is ~ from
- 9:49a mushroom that is going to ~ have hallucinations that
- 9:55are more similar to ~ LSD than any of the other hallucinogens.
- 10:02With mescaline that kind of has its own mechanism of action,
- 10:06and chemically it does differ substantially from
- 10:10~ the LSD/psilocybin chemical structure.
- 10:14PCP, ketamine, we have
- 10:18lecturers here who speak about ketamine.
- 10:20I'm not an expert like they are,
- 10:23so I'm gonna leave ketamine to the side tonight.
- 10:26But as you can see, there is a long list of both chemicals like marinol and cesamet.
- 10:32I actually worked on marinol in ~ emesis years ago,
- 10:39many decades ago.
- 10:41And then we have the experiences as well.
- 10:43So these are just to remind us,
- 10:45those of us who have never had the experience or haven't had it in a long time.
- 10:50I like these; there's a couple of slides that really I connected with
- 10:56as a research scientist that talk about this theory of being
- 11:01a superagonist and how that goes about working.
- 11:06Now, serotonin, one of our monoamine neurotransmitters,
- 11:10is going to bind to its own receptors.
- 11:13Now, as far as I know, there's over seven different kinds of serotonin receptors.
- 11:18Okay? But they're all specific;
- 11:21~ they have binding sites that are specific.
- 11:24So when serotonin's floating around the synapse,
- 11:27it will
- 11:28bind in some way, it might be in this direction,
- 11:30it might be in this direction,
- 11:32but it will bind and connect with the receptor.
- 11:35And then the receptor will do what it normally does,
- 11:39which is to eventually trigger an action potential and propagate signals
- 11:45in the nervous system. This idea, though,
- 11:47that when we have hallucinogens on board,
- 11:51that we're also affecting the glutaminergic neurons,
- 11:55the excitatory amino acid neurotransmitter system,
- 11:59that is going to have effects on our perception,
- 12:04including of sensory. And the idea that we flood our nervous system with
- 12:10serotonin and serotonin-like substances,
- 12:15with the addition of disrupting or changing
- 12:20how glutamate is going to bind to its receptor.
- 12:23So that's kind of my take-home message right up front.
- 12:27Now, since I do teach biochemistry,
- 12:30I have to have some chemistry in here somewhere.
- 12:32And look at this. This is the indole ring of serotonin.
- 12:37We have an aromatic ring. These are all carbons at each of the corners here.
- 12:42And then we have this
- 12:44five-cornered ~ structure that makes it an indole and it has a nitrogen instead
- 12:51of a carbon. If you don't see anything written,
- 12:54it's carbon, right? So here we have carbon,
- 12:56carbon, carbon, carbon, nitrogen.
- 12:59And nitrogen, when combined with hydrogen,
- 13:03is a very polar substance. So it is going to change the way that chemical
- 13:10is going to interact with receptor binding sites.
- 13:12And then, yes, we have an amine group:
- 13:15nitrogen containing hydrogen, a couple of hydrogens.
- 13:19And so again, ~ we have two polar groups in serotonin
- 13:25in and of itself. Here's Psilocybin.
- 13:28And Psilocybin is so interesting because yes,
- 13:31it has that indole ring structure combined with aromatic in this ring.
- 13:36And then it has ~ the nitrogen
- 13:41with open bonds, and that's usually at physiological pH.
- 13:45And so we have this ~ NH bond,
- 13:49but we also have the ability to bind to other sites in addition to
- 13:54the sites where nitrogen might be binding,
- 13:58but it has additional possibilities on it.
- 14:00But the really cool thing about psilocybin is this
- 14:06~ phosphate group here with oxygen attached,
- 14:09right? And phosphate, when you strike a match,
- 14:13that takes energy, right? And so psilocybin brings its own energy
- 14:20to the party, if you will.
- 14:22That will eventually get released.
- 14:23We'll talk about metabolism in a little bit,
- 14:26but we are providing energy to the brain when psilocybin is taken.
- 14:32So the things I've read is that ~ differences between
- 14:37LSD and psilocybin are that the hallucinations that people experience on LSD
- 14:44is more angular. So it's like triangles and squares.
- 14:48And you know, whether they're talking about the visual trails that
- 14:53are imposed on their occipital lobe or ~ you know,
- 14:58just looking at objects, that things are angular and that when people take
- 15:04psilocybin, all the edges are smooth.
- 15:07So their hallucinations are circles and oval
- 15:11Yeah.
- 15:12and shapes that
- 15:13have smooth edges. And I don't know if anybody has ever ~ looked at that,
- 15:19but it's an interesting observation.
- 15:22I don't know how how far I can take that.
- 15:25But there are distinctions between how a person's perception changes when they're
- 15:31taking psilocybin versus ~ LSD.
- 15:33So here's the LSD. Now it's a little hard to tell,
- 15:37but ~ we actually have an indole ring here attached.
- 15:42These are all aromatic rings. LSD is almost like some of
- 15:45our tricyclic ~ antidepressants.
- 15:48Okay? It's got multiple ~ ring structures in it.
- 15:53And this does make it similar to the indole structure that we have
- 15:59for psilocybin as well as serotonin.
- 16:01But as you can see here, in addition to the...
- 16:04Well, this this would be your amine,
- 16:06your primary amine group. But we also have a double-bonded oxygen.
- 16:11So that's an ester group, probably.
- 16:13And then we have additional methyl groups on the end.
- 16:17So it is different. And this actually shows you...
- 16:21this would be another way of expressing the chemical structure.
- 16:25And ~ this would be ~ serotonin.
- 16:29And you see those similarities here for LSD,
- 16:33but then it goes on and it has more expansion.
- 16:35And so the idea, this superagonist idea,
- 16:40~ might involve this additional component.
- 16:44And we'll talk about binding properties later on.
- 16:47This
- 16:48is just to to point out to you
- 16:50that the 5HT2AR receptor
- 16:56has great affinity for just about all of our LSD and psilocybin
- 17:01and of course serotonin, right?
- 17:04It might be having multiple effects.
- 17:07So it might be having hallucinogenic effects where you're actually seeing things
- 17:12or hearing things that are different.
- 17:14A psychedelic effect, although I use those terms interchangeably,
- 17:18the more rigid definition would be the psychological effects
- 17:23of taking hallucinogens. There are non-hallucinogenic analogs,
- 17:29so other drugs that will bind to the 5HT2AR receptor.
- 17:35Think about some of your atypical
- 17:39anti-psychotics, they do have ~ 2A,
- 17:422AC binding sites. So various ones.
- 17:47And then there's this concept of antidepressant effect.
- 17:50And you know, this is what we're trying to study in studies
- 17:56to see if ~ our hallucinogenic drugs can fall under
- 18:01a different schedule under the DEA,
- 18:05because it does have clinical effects.
- 18:08For those of you who aren't familiar,
- 18:10Schedule I, which is where ~ our hallucinogens lie pretty much,
- 18:15means that the drug has no useful medical application
- 18:21and very highly prone to addiction.
- 18:23So ~ that's how we get classified as a Schedule I drug.
- 18:29And so right now our
- 18:32hallucinogens as a broad category do fall under that ~ schedule.
- 18:37But if we're able to really demonstrate antidepressive effects,
- 18:42then it can move over into probably Schedule II.
- 18:45But it's coming. It's coming down the pike.
- 18:49So I'm not going to test anybody on all the structures
- 18:53of classical serotonergic psychedelics.
- 18:57But I did want to point out, in addition to ~ LSD down here,
- 19:02and here's psilocybin, and there's our beautiful indole amine structure,
- 19:07we do have MDMA that is thought to primarily bind
- 19:13to glutamate, but has our indole structure.
- 19:18Now it has a slightly different
- 19:21chain off of it, but it does have that indole structure.
- 19:25This is ibogaine, which our current president has recently expressed interest
- 19:31in ~ seeing more research done on this drug,
- 19:34and it does in fact have the serotonergic component to it.
- 19:39This is DMT. This is the LSD.
- 19:43And so here's our indole group.
- 19:44~ This is MDMA, and so it's it doesn't quite have an indole group to it,
- 19:51but it does have another five-cornered structure,
- 19:56and then it has its nitrogen ~ amine group sticking out.
- 20:01And these amine groups are very important for binding to receptors.
- 20:06Here's ketamine. Ketamine is different,
- 20:09but it does have that amine group sticking out.
- 20:13And it does have the potentials.
- 20:16It's a little hard to see on two dimensions,
- 20:19but in three dimensions, you would be able to see that there would
- 20:23be potential for additional bonds.
- 20:26So it's kind of like ~ taking the bottom out of this ring here.
- 20:31And then of course here's serotonin.
- 20:33Now, mescaline I've kind of left on its own for a little bit because
- 20:38it certainly has its own hallucinogenic properties and psychedelic properties,
- 20:43but it is different from these indole amine ~ structures.
- 20:47This is an aromatic ring, it's just drawn a little differently.
- 20:51You know, it's kind of like Spanish and English and French,
- 20:55you know.
- 20:56We have different languages, and in chemistry,
- 20:58there's different ways to draw things.
- 21:01So it has a lot of methyl groups on it.
- 21:03Here's three methyl groups; has an ether bond.
- 21:06It has a primary amine, but no indole ring.
- 21:10And so some of the differences between mescaline and our other psychedelics might
- 21:17be because it is lacking
- 21:19that ~ indole ring but you will experience the profound psychogenic
- 21:25or psychedelic effects of mescaline.
- 21:29Which part is really essential for each of those components of the overall effect
- 21:36of taking hallucinogens? That's not clear now.
- 21:39But it might be
- 21:41that if you added an indole ring onto here,
- 21:44that you might have the ultimate or penultimate ~ hallucinogen there.
- 21:50I find mescaline very interesting because it is natural,
- 21:55first of all, and that is something that ~ the people who think there's
- 22:00a difference between ~ psychedelics and hallucinogens and ~ psychopharmacology
- 22:07that, ~ you know, they are a little off target there because natural products
- 22:12are really the source of most of our medications,
- 22:16not just psychogenic medications.
- 22:19You know usually it's the dose;
- 22:21the dose is the poison ~ and if there are too many side effects of
- 22:25a medication ~ then a person's not going to take it.
- 22:29But interestingly, ~
- 22:31people will take mescaline, they will take psilocybin,
- 22:35even though they have ~ pretty profound adverse reactions:
- 22:40vomiting, nausea, but people seem more connected with taking
- 22:47something derived from a plant.
- 22:48And this is the structure circling,
- 22:51I like those.
- 22:52But mescaline does have a unique structure in and of itself.
- 22:56And
- 22:56you can tell I figured since I'm talking about hallucinogens,
- 22:59I should have lots of things flashing and with color.
- 23:02But this is a very interesting study.
- 23:05This is out of Washington University,
- 23:07and this is a heat map of brain activity that they looked at before treatment,
- 23:14and you can see that most of the colors are blue and green.
- 23:17This is during a trip on psilocybin.
- 23:20And you can see, and it's flashing in and out here,
- 23:23but you can see that there are areas of the brain that
- 23:29do experience profound changes in activity patterns.
- 23:33And so, and then long term, if you stop taking it,
- 23:38but after a while, ~ the patterns in the brain do return to
- 23:44pre-psilocybin levels. And so it's really kind of interesting
- 23:49in using technology now like this to be able to illustrate that when
- 23:56people take hallucinogens... and they go through all these different experiences,
- 24:01right? ~ feelings, ~ sensory changes,
- 24:06thoughts of profound significance to that person.
- 24:10That they are all related and activated throughout the brain,
- 24:14right? Making it as attractive in some ways as ketamine,
- 24:20if we can control the administration of it,
- 24:23for working on depression and PTSD.
- 24:28So here's our psilocybin mushrooms.
- 24:31When I lived in Hawaii, I had a cow pasture and
- 24:35psilocybin mushrooms were popping up all over the place.
- 24:38And I don't know if the cows were aware of that,
- 24:41but you know, they grow pretty commonly ~ in agricultural areas.
- 24:47And also in the woods, you can find psilocybin mushrooms.
- 24:51But here's the chemistry of what happens with psilocybin.
- 24:55What's interesting is- so here's our molecule,
- 24:58and so
- 24:59psilocybin is going to go through a metabolic change that converts it to psilocin,
- 25:05which is a active metabolite, right?
- 25:08So psilocybin can be active and then it converts to psilocin and it's
- 25:14an active metabolite as well. So in some ways you can think of psilocybin
- 25:18as the parent drug.
- 25:19And ~ there are additional metabolites that break off.
- 25:23Here in this ~ little box here it says FE4.
- 25:27Now that's referring to iron. We have this whole group of enzymes.
- 25:34We usually just talk about them in the liver,
- 25:36but they're actually ubiquitous around the body,
- 25:39and they're called CYP enzymes for cytochrome P450.
- 25:44And so the thing that makes ~ CYP enzymes what they are
- 25:50is the presence of heme. And in the center of heme is iron.
- 25:55So as it turns out, there are CYP enzymes involved
- 26:01in the metabolic path to create psilocin.
- 26:04And then what you can see here is that we have
- 26:09multiple additional metabolites that come out of the psilocin that
- 26:15are phase two metabolism.
- 26:18So we have phase one, which is CYP enzymes.
- 26:21Phase two metabolism is when we're trying to make
- 26:26a compound less lipophilic so that it can get eliminated through the urine.
- 26:33Only hydrophilic substances
- 26:36can pass from the bloodstream into the tubules of the kidney
- 26:42and get passed out through the urine.
- 26:44So when we have a couple of different phase two enzymes involved,
- 26:50that means that we're trying to make the psilocin
- 26:54~ more hydrophilic.
- 26:58And you can also see we have aldehydes,
- 27:01we have MAO, monoamine oxidase.
- 27:03And then one interesting thing is that psilocin has a very active metabolite,
- 27:10and that is serotonin. So in addition to the parts
- 27:14of psilocybin that mimic serotonin at the binding site,
- 27:19we also have a recycling of the portion of psilocybin that will create
- 27:26serotonin.
- 27:27Okay, now I know this is small,
- 27:29but this is just to show you that we have multiple chemical classes that fall under
- 27:35this
- 27:35hallucinogen category: tryptamine ~ for LSD,
- 27:41tryptamine for psilocybin, phenylethylamine for MDMA,
- 27:46mescaline is also in that phenylethylamine group.
- 27:50And then here's ~ DMT with tryptamine as well.
- 27:55Tryptamine is part of the pathway
- 27:59for plants to make serotonin. We mammals make serotonin from
- 28:05tryptophan, right? So I just wanted to make sure we were clear on it.
- 28:10These products that are up here are derived from tryptamine following
- 28:16the pathway that plants use for synthesizing or mimicking serotonin.
- 28:22This slide I've included ~ just to make sure I've satisfied my personal goal
- 28:28of making chemistry a little less scary,
- 28:31maybe. And I know it's very small,
- 28:33so you'll have to ~ blow it up,
- 28:34but I did give you the link to the article that this comes from.
- 28:38And it has compounds that act at serotonin binding sites.
- 28:43It also has
- 28:44compounds that act like amphetamine.
- 28:47Those that fall into that class of phenylethylamine usually
- 28:53are doing what at least part of it,
- 28:56what amphetamines do. Now the interesting thing,
- 28:59when we think of amphetamines and ADHD,
- 29:03we think about
- 29:05the amphetamine spilling out noripinephrine and dopamine.
- 29:08But they also spill out serotonin,
- 29:12but we just don't really talk about that when we talk about ADHD treatments.
- 29:18So is there a hallucinogenic property
- 29:22to our ~ drugs that act
- 29:27like amphetamines? And for those of you who don't know,
- 29:29amphetamines are going to cause vesicles within the neurons to spill
- 29:35out their content. And what happens is,
- 29:38after a while, you've depleted the energy in that neuron to make more vesicles.
- 29:45And so, you know, when somebody ~ is using amphetamines
- 29:50to get high and they have a crash,
- 29:53that
- 29:54crash is because they have depleted their neurons of neurotransmitter.
- 29:59And so is it the serotonergic component that we don't focus on when we're thinking
- 30:05of ADHD but is it possible that there are potential drugs that
- 30:10can be developed that would help us with ADHD
- 30:15and enhance the psychic part
- 30:18of how these drugs work? It's an interesting idea.
- 30:21I'm not really sure yet. Anyway,
- 30:23so you can classify your hallucinogens into these various categories.
- 30:28This idea that activation of the 5HT2A receptor enhances
- 30:35glutamate
- 30:36excitation in certain layers of the prefrontal cortex and then it gets released,
- 30:42going from the waystation of the midbrain or forebrain from the thalamus
- 30:48up to the cortex. So what is getting filtered is essentially one of
- 30:53the roles that glutamate plays.
- 30:55Glutamate and GABA are always balancing each other out.
- 31:00But what happens, or one of the theories,
- 31:02is that we affect the release of glutamate from glutaminergic neurons
- 31:08and we change the activity of the receptors.
- 31:14Because when we bind to the serotonin receptor,
- 31:17if this is our glutamate receptor normally,
- 31:19and this would be, you know, your ion channel,
- 31:23if LSD or serotonin are binding and we can make that channel open wider,
- 31:29that's a conformational change in the receptor that we might be seeing.
- 31:34And we all know that glutaminergic neurons are very involved
- 31:39in their interneurons and very involved in cognitive processing.
- 31:43Is it that
- 31:44LSD and psilocybin
- 31:47are modifying glutaminergic receptors
- 31:52in the prefrontal cortex? Is that a possibility?
- 31:56It certainly is. But there's this idea that we're either changing
- 32:01the receptor structure to enhance glutaminergic activity,
- 32:06or we're changing the way that glutamine is getting released
- 32:11from the neuron. pKa's are generally pretty high for our
- 32:17~ hallucinogens in general. I pulled these from various sources.
- 32:21But the idea that our pKa,
- 32:25our ~ acid dissociation constant is on
- 32:29the basic side means that
- 32:33these drugs will go through pharmacokinetics,
- 32:36Armor Coke and
- 32:37absorption in particular, similarly to how our ~ SSRIs,
- 32:42many of our psychotropic drugs work because they all start out with
- 32:48~ high pKa, so that they will get passed from the stomach into
- 32:54the ~ intestine, where they can get absorbed at a different rate than if they just
- 33:00pass right through the stomach lining.
- 33:02So they're all probably going to act more like ~ a number of our psychotropic meds,
- 33:08which is good because the goal is to get our hallucinogens up to the brain
- 33:14to have their effects.
- 33:15This is looking at
- 33:17nicotinic receptors and glutaminergic ~ receptors.
- 33:21We're not talking about nicotine today,
- 33:23although ~ you know, when we talk about ritual practices,
- 33:27tobacco is a very important part of Native American practices.
- 33:32And so it may be that when used in ritual ways,
- 33:37that we're also affecting our glutamine receptors with nicotine,
- 33:44but
- 33:44I just wanted, I like this image because it does give you that idea of ways that
- 33:50you can modify the glutaminergic receptor by modifying other receptors.
- 33:54This is very important to the concept that I'm talking about.
- 33:58So what happens is
- 34:00the ~ binding to 5HT2A receptors is going
- 34:06to change certain glutamate receptors.
- 34:09Not all of them, but it's going to change the mGlu2 receptor.
- 34:14~ And it forms a complex.
- 34:17So this would be LSD and this would be LSD and its effects
- 34:25on the glutaminergic receptor.
- 34:27And this was an animal model that they used,
- 34:30but it's when this component,
- 34:34the changing of the ~ glutaminergic receptor,
- 34:38happens that these mice show ~ you know,
- 34:43certain behaviors associated with taking LSD.
- 34:47So it does seem that
- 34:49some, at least this property of head movement,
- 34:52is sensitive to that change in ~ the glutamate receptor.
- 34:59I love crystallography. So this is literally supposed to represent each
- 35:05of our transmembrane domains that our receptors make up.
- 35:10This would be LSD binding to the-
- 35:12this is a 2B receptor, but the mechanism is thought to be similar.
- 35:16So this is our LSD; it's binding here,
- 35:20and then the ribbons will allow
- 35:23your ions to come inside. ~ They did identify different parts
- 35:29of LSD that activate the receptors differently.
- 35:34So might be responsible for additional effects.
- 35:40The other thing I want to talk about are CYP enzymes.
- 35:42And this is very important because ~ your patients
- 35:46may be taking hallucinogens in addition to medications that you prescribe
- 35:52or they're getting prescribed by somebody else.
- 35:55But you should be aware of the fact that if they are taking an SSRI or an SNRI,
- 36:02and they're taking Psilocybin or LSD,
- 36:06they may create problems with the availability
- 36:11of receptors and binding sites on the enzymes for the drug that you're prescribing.
- 36:18So LSD involves ~ 1A2,
- 36:222C9, and 3A4 CYP enzymes
- 36:28for its metabolism.
- 36:30~ And also 2D6 and 3A4 for another pathway.
- 36:35And so these are enzymes that just about all
- 36:41of your psychotropic drugs depend on for their proper metabolism.
- 36:47And so if they're taking LSD along with psychotropic meds that you've prescribed,
- 36:53you want to make sure that either they've taken into account the half-lives
- 36:58of the LSD versus the medication they're taking.
- 37:02If they're taking fluoxetine, for example,
- 37:05the very long half-life, ~ they may end up with something called serotonin syndrome.
- 37:10We all know basically that's a bad thing.
- 37:13And so this is just kind of to illustrate for psilocybin
- 37:18that we also include ~ the CYP enzymes 2D6 and 3A4;
- 37:23they just call it CYP450 here.
- 37:27But ~ it is this modification through
- 37:33the CYP enzyme that might create a drug-drug interaction in your patients.
- 37:39Ketamine is fully legal to prescribe in all 50 states.
- 37:44I don't know that there are prescribing psychologists who prescribe ketamine,
- 37:48maybe in New Mexico, but for the most part,
- 37:51it's a physician or psychiatrist who's a physician plus.
- 37:57Psilocybin is legal in certain states,
- 38:01and all other psychedelics still remain on our ~ Schedule I list.
- 38:07And this is just a little bit more detail about that.
- 38:09These are the new guidelines that came out last week.
- 38:13And they're still in the process.
- 38:15This review process within the FDA started,
- 38:19I think, in 2024 for consideration of clinical studies that
- 38:25can be done with hallucinogens.
- 38:28Designing the study itself is a little challenging because it's hard
- 38:33to use traditional placebos. And there really are
- 38:37not any DEA drugs on any of the other schedules that
- 38:43you could compare directly; you know,
- 38:46use as a positive control, if you will.
- 38:49So we do have to be a little bit more creative in the way we design these studies
- 38:54to do the comparisons. ~ Sometimes they'll do pre and post.
- 38:58~ You know, we do have crossover ~ studies that can be done.
- 39:03There are approaches that can be taken,
- 39:05but it is a specific challenge to hallucinogenic drugs.
- 39:10And if you look at what the ~ marijuana industry has done in terms of
- 39:16creating much more uniform ~ definitions and dosing and things like that,
- 39:22it's really remarkable to me, and make it clear that with the right thinking that
- 39:28goes into ~ this process, that we can come up with appropriate study designs that
- 39:34would be used for evaluating ~ psychedelics.
- 39:38So this is just more from the guidelines that they're creating.
- 39:42This link will take you to the document itself.
- 39:46This link takes you to the preamble about ~ this guidance document that's being
- 39:52created. The net effect is probably going to be moving at least
- 39:58the natural psychedelics to Schedule II.
- 40:02All right. Unfortunately, I am not going to have time to go through all my plants.
- 40:06These are substances that are used in ritual practices by Native American,
- 40:11Native Indian cultures. I just wanted to point out that,
- 40:16you know, for the use of tobacco,
- 40:19for example, nicotine is considered an inducer of
- 40:25the 3A4 enzyme in addition to other components of tobacco smoke,
- 40:31but ~ nicotine itself is an inducer of 3A4,
- 40:36~ the CYP enzyme. And so what that means is you're going to metabolize more quickly.
- 40:43So if you're taking a given dose of a medication,
- 40:46the effect will run out sooner,
- 40:48essentially. And then peyote,
- 40:52mescaline. ~ I just want to point out that it does have some binding properties
- 40:59at ~ serotonin receptors, but you saw the structure,
- 41:03it's really not like an indolamine,
- 41:06so it's not going to work quite as efficiently at those receptors.
- 41:12~ For peyote, ~ this is ~ some of the pharmacology
- 41:18and adverse reactions to expect.
- 41:20And you know it's interesting to me though that people are willing
- 41:24to take peyote and go through these adverse effects,
- 41:28knowingly will experience those,
- 41:30~ to reach the place where they can have that ~ psychedelic experience.
- 41:36So, in terms of harm for all of these drugs,
- 41:40you can see that heroin, ~ methamphetamine are very high,
- 41:46and our hallucinogens for the most part are much lower on the scale
- 41:52of overall harm.
- 41:53For those of you who are not in the prescribing psychology field,
- 41:57I just wanted to point out that we do have our nine states now,
- 42:01and Vermont and Hawaii. This is the first year we have added two states in one year.
- 42:07So we are moving forward. And now we can officially be from sea to shining sea,
- 42:13we have prescriptive authority.
- 42:15Division 55, please consider joining if you are not already a member.
- 42:19~ We just grew to the highest number this year.
- 42:23I think it's 1,070–1,080 people.
- 42:28So we are a growing field and please be part of it.
- 42:31Any questions?
- 42:33So how 5HT2A receptor agonists alter cortical network connectivity?
- 42:39It is a great question. So that image that I showed you with
- 42:44the flashing energy levels on the brain,
- 42:48connectivity between the cortex,
- 42:51the thalamus, and the striatum,
- 42:54which is so interesting in and of itself,
- 42:56is essential for developing resilience,
- 43:00personal resilience. And there are studies that have been done,
- 43:04~ mostly out of Alabama that I've seen,
- 43:07but there might be some other studies.
- 43:09And I can send you these references if you email me.
- 43:12And they have shown
- 43:14that people with substance use disorders have unusually
- 43:19low levels of connectivity in that triangle pathway.
- 43:25And that as people go through abstinence
- 43:29and develop skills for ~ staying off of medications,
- 43:36that the activity in those pathways increases.
- 43:41So it's not just a question of something binding to a receptor.
- 43:46It is this strengthening of the firing between those regions
- 43:53that contributes to our ability to utilize therapy
- 43:59for treating anxiety and depression.
- 44:02And so those studies where we're seeing this increase in activity
- 44:09in the prefrontal cortex, that in relation to the hallucinogens
- 44:15is part of that pathway. That activation of that pathway then leads
- 44:20to excitation levels throughout the brain.
- 44:24I hope that makes sense.
- 44:26Yeah, you're just getting a lot of positive feedback,
- 44:28Dr. Steinman. What an amazing presentation.
- 44:30Thank you so much. And Dr. Kapalka,
- 44:33thank you for attending too.
- 44:34Thank you, Dr. Steinman. It is always great to hear your presentations.
- 44:38And ~ those of you in the audience who would like to learn more or who would like
- 44:42to learn more about psychopharmacology and hear Dr.
- 44:46Steinman speak about this and many other topics,
- 44:50~ we are enrolling students ~ to start in our fall cohort,
- 44:56which starts August 24. So we would love to hear from you.
- 45:00And if anybody's interested in ~ prescribing in Hawaii,
- 45:04please let me know because we have this three-year pilot study.
- 45:08We've started working on it already.
- 45:11Congratulations, Dr. Steinman and the whole Hawaiian team.
- 45:15This has been many years in the making,
- 45:18as many of us know. So hearty congratulations.
- 45:22And yes, we would love to see many prescribers ~ come to Hawaii.
- 45:27Thank you, Dr. Steinman and Dr.
- 45:28Kapalka. Again, everyone, thank you so much for attending.
- 45:31These are always amazing presentations.
- 45:33Mahalo.